Long-term azithromycin may improve lung function in children with cystic fibrosis

Lancet

Volumn 351, Issue 9100, 1998, Pages 420-

  Jaffé, Adam ^a   Francis, Jackie ^b   Rosenthal, Mark ^b   Bush, Andrew ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; MACROLIDE;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

EID: 0344624839     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78360-4     Document Type: Article

References (5)

1. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49: 531-32.
2. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145-49.
3. Sakito O, Kadota J, Kohmo S, Abe K, Shirai R, Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in broncho alveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-48.
4. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997; 52: 915-18.
5. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995; 99: 26S-30S.